Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality8/10

ERAS-0015 data boosts ERAS pipeline toward registration-readout catalysts 2027

Aug 11, 2026, 4:09 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong early data for ERAS-0015 and a robust financing runway improve near-term visibility and potential for milestone-driven upside; however, outcomes remain early-stage and data-dependent.

AI summary

What happened, with direct paths to the underlying reporting

ERAS-0015 updated U.S. trial data show 57% uORR<8wk in 2L+ KRAS G12X PDAC with favorable tolerability, and initial doses combined with panitumumab show no DLTs. Erasca also outlined three potentially registration-enabling trials for 2027 and expects ERAS-4001 data in H2 2026, supported by a $632.5 million upsized financing that strengthens the balance sheet for pipeline catalysts.

ERAS-0015 shows 57% uORR<8wk in 2L+ KRAS G12X PDAC; tolerability solid.
16–32 mg panitumumab combos show no DLTs; cohort escalation ongoing.
Upsized financing: ~$632.5M gross; strengthens balance sheet.
Three registration-enabling ERAS-0015 trials planned for 2027; H1 2027 readouts.
ERAS-4001 data due H2 2026; Phase 1 monotherapy data in 2026–2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.